Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide ...